证券代码：870199 证券简称：倍益康 公告编号：2025-052 四川千里倍益康医疗科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 √特定对象调研 □业绩说明会 二、 投资者关系活动情况 活动时间：2025 年 5 月 29 日 活动地点：公司会议室 参会单位及人员：银河证券、融贤汇金基金、中国证券报 上市公司接待人员：公司董事长、总经理：张文 先生 证券事务代表：奚旺 先生 三、 投资者关系活动主要内容 本次投资者关系活动的主要问题及公司对问题的回复概要如下： 1、请问今年以来，公司海外市场销售如何？便携式气压按摩系统目前市场 推广进度如何？ √媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 答：公司在研发投入方面有着详细的规划布局，研发费用是根据公司战略、 市场需求、项目进展及财务状况等多方面因素综合决定，而非单一阈值限定。 答：今年公司海外市场销售就目前来看，还是比较稳定。便携式气压按摩系 统（压缩靴）作为 ...

Core Insights - The company reported a strong performance in 2024, with revenue of 8.978 billion yuan, a year-on-year increase of 9.69%, and a net profit of 0.695 billion yuan, up 19.81% [1] - The first quarter of 2025 continued the growth trend, achieving revenue of 2.605 billion yuan, a 36.47% increase year-on-year, and a net profit of 0.249 billion yuan, up 36.26% [1] - The dual-engine model of "medical + consumer" is driving significant growth through both organic growth and acquisitions [1] Consumer Business Performance - The consumer segment, represented by All Cotton Era, achieved revenue of 4.99 billion yuan in 2024, a 17.1% increase, and 1.34 billion yuan in Q1 2025, a 28.8% increase [2] - The cotton soft towel business generated 1.56 billion yuan in revenue, up 31.2%, while the female care product line saw revenue growth to 0.7 billion yuan, an 18.0% increase [2] - The company is focusing on health and environmental concepts, enhancing product offerings in homewear and intimate apparel, with adult clothing revenue reaching 0.96 billion yuan, a 15.4% increase [2] Channel and Brand Strategy - The company adapted to online consumption trends, achieving online revenue of 3.07 billion yuan, an 18.9% increase, with Douyin platform revenue growing over 109% [3] - The company opened 92 new stores, bringing the total to 487, and increased its membership base to nearly 61 million, a 15.8% growth [3] - The brand's 15th anniversary celebration reinforced its commitment to sustainability and enhanced consumer emotional connection [3] Medical Segment Performance - The medical segment achieved revenue of 3.9 billion yuan in 2024, maintaining positive growth despite previous high base effects, with a 20.3% increase in other categories excluding pandemic-related products [4] - In Q1 2025, the medical segment revenue reached 1.25 billion yuan, a 46.3% increase, driven by both organic growth and expansion [4] - Key product lines such as high-end dressings and surgical consumables showed significant growth, with high-end dressings generating 0.78 billion yuan, a 31.2% increase [4] Global Expansion and Innovation - The company acquired U.S. medical consumables firm GRI, contributing 0.29 billion yuan in new revenue and enhancing its global supply chain [5] - Overseas revenue grew by 37.7%, accounting for over 54% of total medical revenue, indicating a strong international presence [5] - The company holds 1,087 R&D patents and continues to innovate in high-end consumables and chronic disease management [5] Shareholder Returns and Future Strategy - The company plans to distribute a total cash dividend of 6.50 yuan per 10 shares, representing 54.43% of net profit, reflecting strong cash flow management [7] - The chairman outlined a strategic goal of "century-long stability and brand enhancement," focusing on operational excellence, global expansion, brand building, talent strategy, sustainable development, and product innovation [7][8] - The dual focus on medical and consumer sectors is expected to drive sustainable growth and establish the company as a leader in global health and quality consumption [8]